Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Pneumococcal polysaccharide vaccine Stories

2013-09-04 08:19:59

The use of 4 different 13-valent pneumococcal conjugate vaccine immunization schedules in healthy term infants resulted in no statistically significant differences in antibody levels between the infants after the booster dose at 12 months of age for almost all serotypes, according to a study in the September 4 issue of JAMA. "The World Health Organization (WHO) estimated that more than 800,000 children younger than 5 years died from pneumococcal disease in 2000, making it the leading...

2013-07-11 13:05:23

Children who receive a vaccine to prevent blood and ear infections, appear to be reducing the spread of pneumonia to the rest of the population, especially their grandparents and other older adults. Results of a new Vanderbilt study, funded by the Centers for Disease Control and Prevention (CDC), and published in the July 11 issue of the New England Journal of Medicine show infant vaccination against pneumococcal bacteria since 2000 has reduced pneumonia hospitalization by more than 10...

2013-05-22 12:30:46

PASADENA, Calif., May 22, 2013 /PRNewswire/ -- The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published today in Vaccine. The U.S. Food and Drug Administration approved PCV13 for use beginning in 2010 after a series of trials. These trials found that PCV13, which protects against a broader range of pneumococcal types than the...

2013-01-04 12:23:11

ZURICH-SCHLIEREN, Switzerland, Jan. 4, 2013 /PRNewswire/ -- GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced that Janssen Pharmaceuticals, Inc. (JPI), has signed an exclusive license agreement and entered into a three-year research and development collaboration to develop a multi-valent bacterial vaccine employing GlycoVaxyn's bio-conjugation technology. "Bacterial pathogens that exist in multiple pathogenic strains pose significant challenges for developing...

2012-12-21 16:23:02

WHITEHOUSE STATION, N.J., Dec. 21, 2012 /PRNewswire/ -- A gallon of gas cost 62 cents, the first Star Wars opened in movie theaters and disco ruled the dance floor. But 1977 was also a milestone year in science, technology and health care. In 1977: Apple Computer Inc. is incorporated The first MRI scan is performed on a human body The first pneumococcal polysaccharide vaccine is approved Science, technology and health care have evolved in many ways since 1977. For example, the...

Pneumococcal Vaccine To Be Tested In Older Adults
2012-10-16 06:21:03

Connie K. Ho for redOrbit.com — Your Universe Online Scientists recently revealed that they plan to study the pneumococcal vaccines in older adults to determine if there´s a strong immune response due to a higher dosage of the vaccine. The study, funded by the National Institute of Health (NIH) as well as the National Institute of Allergy and Infectious Diseases, looked at a group of adults who previously received a vaccine that worked against pneumonia and other pneumococcal...

2012-05-07 19:44:55

The vaccine given to children to immunize against serious pneumococcal disease does not offer full protection, reveals research from the Sahlgrenska Academy at the University of Gothenburg, Sweden, finding that the number of cases diagnosed has tripled over the past 50 years. Each year an estimated 1 million children worldwide die as a result of pneumococcal disease. Worst affected are those in poor countries, but pneumococcal bacteria cause disease and suffering in all age groups and in...

2012-02-09 14:34:00

UPPER NYACK, N.Y., Feb. 9, 2012 /PRNewswire-USNewswire/ --The 42 million people in the U.S. who are between 50 and 65 may soon have a new vaccine to prevent pneumococcal pneumonia - a virulent form of the disease estimated to infect between 5 and 10 million people a year in the United States, and killing between 40,000 to 70,000 annually, according to the Global Healthy Living Foundation. "This is a chance to positively impact the vaccination rate for adults, and hopefully save lives and...

2012-01-30 08:12:12

Genetics has provided surprising insights into why vaccines used in both the UK and US to combat serious childhood infections can eventually fail. The study, published today in Nature Genetics, which investigates how bacteria change their disguise to evade the vaccines, has implications for how future vaccines can be made more effective. Pneumococcus (Streptococcus pneumoniae) causes potentially life-threatening diseases including pneumonia and meningitis. Pneumococcal infections are...

2011-12-30 12:56:00

SILVER SPRING, Md., Dec. 30, 2011 /PRNewswire-USNewswire/ -- Prevnar 13, a pneumococcal 13-valent conjugate vaccine, was approved today by the U.S. Food and Drug Administration for people ages 50 years and older to prevent pneumonia and invasive disease caused by the bacterium, Streptococcus pneumoniae. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Pneumococcal pneumonia, caused when the bacterium Streptococcus pneumoniae infects the lungs, is the most common disease...